Go Pro
→ Gold majors have a big problem (From Golden Portfolio) (Ad)tc pixel Free PBMWW Stock Alerts

Psyence Biomedical (PBMWW) Competitors

$0.03 +0.00 (+2.12%)
As of 09/11/2026 03:59 PM Eastern
Compare

PBMWW vs. SXTPW, BFRIW, CINGW, CLVR, and CMRAW

Should you buy Psyence Biomedical stock or one of its competitors? Psyence Biomedical's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Clever Leaves (CLVR), and Comera Life Sciences (CMRAW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Psyence Biomedical compare to 60 Degrees Pharmaceuticals?

Psyence Biomedical (NASDAQ:PBMWW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat 60 Degrees Pharmaceuticals' score of 0.44 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company Overall Sentiment
Psyence Biomedical Very Positive
60 Degrees Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Psyence BiomedicalN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Psyence BiomedicalN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Psyence Biomedical on 2 of the 3 factors compared between the two stocks.

How does Psyence Biomedical compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Psyence Biomedical (NASDAQ:PBMWW) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Psyence BiomedicalN/AN/AN/AN/AN/A

In the previous week, Biofrontera had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat Biofrontera's score of 0.44 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Psyence Biomedical Very Positive

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Psyence Biomedical N/A N/A N/A

Summary

Biofrontera beats Psyence Biomedical on 2 of the 3 factors compared between the two stocks.

How does Psyence Biomedical compare to Cingulate?

Psyence Biomedical (NASDAQ:PBMWW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Cingulate had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 2 mentions for Cingulate and 1 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat Cingulate's score of 1.43 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company Overall Sentiment
Psyence Biomedical Very Positive
Cingulate Positive

Company Net Margins Return on Equity Return on Assets
Psyence BiomedicalN/A N/A N/A
Cingulate N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Psyence BiomedicalN/AN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Summary

Psyence Biomedical and Cingulate tied by winning 1 of the 2 factors compared between the two stocks.

How does Psyence Biomedical compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Psyence Biomedical (NASDAQ:PBMWW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Psyence Biomedical has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Psyence BiomedicalN/AN/AN/AN/AN/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Psyence Biomedical had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Clever Leaves. Psyence Biomedical's average media sentiment score of 1.89 beat Clever Leaves' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Psyence Biomedical Very Positive

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Psyence Biomedical N/A N/A N/A

Summary

Clever Leaves beats Psyence Biomedical on 3 of the 5 factors compared between the two stocks.

How does Psyence Biomedical compare to Comera Life Sciences?

Psyence Biomedical (NASDAQ:PBMWW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Psyence BiomedicalN/AN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Psyence Biomedical had 1 more articles in the media than Comera Life Sciences. MarketBeat recorded 1 mentions for Psyence Biomedical and 0 mentions for Comera Life Sciences. Psyence Biomedical's average media sentiment score of 1.89 beat Comera Life Sciences' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company Overall Sentiment
Psyence Biomedical Very Positive
Comera Life Sciences Neutral

Company Net Margins Return on Equity Return on Assets
Psyence BiomedicalN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

Psyence Biomedical beats Comera Life Sciences on 2 of the 3 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBMWW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBMWW vs. The Competition

Export
MetricPsyence BiomedicalPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.43B$7.15B$12.71B
Dividend YieldN/A2.62%2.56%11.15%
P/E RatioN/A797.20272.9825.27
Price / SalesN/A751.08646.1289.59
Price / CashN/A89.2577.0451.44
Price / BookN/A10.3910.336.20
Net IncomeN/A$2.83B$3.49B$358.27M
7 Day PerformanceN/A-3.66%-3.33%-2.36%
1 Month PerformanceN/A0.82%-0.42%-2.77%
1 Year PerformanceN/A3.50%19.22%7.64%

Psyence Biomedical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBMWW
Psyence Biomedical
N/A$0.03
+2.1%		N/A-1.4%$0.00N/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
-15.5%		N/A-34.1%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.03
flat		N/A-81.5%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
-4.2%		N/A-87.4%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PBMWW) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Elon Musk to Trigger Next AI Wave on November 11th?
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel